CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced that it has completed enrollment of the Phase 1b FORTRESS study of NG-350A, an oncolytic immunotherapy for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC). The FORTRESS study enrolled 33 participants with pMMR LARC across seven sites in the United States and the United Kingdom to evaluate the effic
